Epidemiology and Pharma Market Access Potential
When discussing pharma pricing analysis, we are very careful to examine all of the strategic options. In order to maximize market access and pharma reimbursement, it is critical understand all of the compounding pricing factors. In the past, we have scrupulously examined global prescription revenues across various therapeutic disease indications. Today we are analyzing global disease incidence and using it to forecast pharmaceutical sales numbers, globally.
Particularly, I was very excited about the pharmaceutical earnings potential in emerging Asian economies. But when I brought my findings to the desk of my mentor, Dr. Gorkin, he quickly reminded me of the need to quantify outcomes and understand the timeline upon which impact could be felt. In the competitive world of pharma pricing, this is especially true.